iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN)

Rhea-AI Summary

iCAD has partnered with Microsoft to integrate its AI-powered mammography solutions into Microsoft's Precision Imaging Network (PIN). The collaboration enables automated patient reporting through PowerScribe integration, connecting over 17,000 healthcare facilities nationwide.

Key highlights:

• ProFound AI Breast Health Suite will be cloud-hosted on Microsoft's network, offering streamlined AI-driven insights for breast health detection
• The recently FDA-cleared ProFound Detection Version 4.0 shows 22% improvement in detecting complex cancer subtypes and 18% reduction in false positives
• The integration supports iCAD's transition to a SaaS model while expanding market reach
• The solution incorporates prior mammograms into AI analysis for better assessment of changes over time

The technology will be showcased at the SIIM25 Annual Meeting + InformaticsTECH Expo in Portland from May 21-23, 2025.

Positive

• Strategic collaboration with Microsoft expands market reach through integration with PowerScribe, used by majority of U.S. radiologists
• Integration into Microsoft's Precision Imaging Network connects iCAD to over 17,000 healthcare facilities nationwide
• Recent FDA clearance for ProFound Detection Version 4.0 shows 22% improvement in detecting complex cancer subtypes
• Technology advancement demonstrates 18% reduction in false positives, improving operational efficiency
• Business model transition to SaaS aligns with modern healthcare technology trends

Negative

• None.

Insights

Healthcare Technology Analyst

Microsoft partnership extends iCAD's AI mammography tech to 17,000+ facilities with improved cancer detection capabilities and seamless radiologist workflow integration.

The iCAD-Microsoft collaboration represents a significant advancement in breast cancer detection technology distribution. By integrating iCAD's ProFound AI suite with Microsoft's Precision Imaging Network and PowerScribe platform (used by most U.S. radiologists), the partnership addresses two critical barriers to AI adoption: workflow integration and distribution reach.

The recently FDA-cleared ProFound Detection Version 4.0 delivers 22% improvement in detecting complex and aggressive cancer subtypes over previous versions, with particular enhancements for dense breast tissue. The technology also achieves an 18% reduction in lesion markings, minimizing false positives while streamlining radiologist workflows.

From a technical perspective, the integration of patient priors into the AI analysis allows radiologists to better assess changes over time, supporting more personalized screening assessments. The cloud-hosted implementation across Microsoft's network connecting 17,000+ healthcare facilities eliminates on-premise deployment challenges that typically slow healthcare technology adoption.

This partnership effectively transforms how AI mammography solutions are delivered, creating a frictionless path for radiologists to access advanced detection tools within their existing workflow systems rather than through separate platforms requiring additional steps.

Financial Analyst

Strategic Microsoft partnership accelerates iCAD's SaaS transition and market penetration through integration with PowerScribe platform used by majority of U.S. radiologists.

This Microsoft collaboration represents a strategic market expansion for iCAD by leveraging Microsoft's extensive healthcare network to distribute their AI mammography solutions. The partnership directly supports iCAD's stated growth strategy of "expanding the reach of our industry-leading technology, driving deeper market penetration, and advancing our transition to a SaaS model."

Integration with PowerScribe, the dominant radiology reporting platform in the U.S. healthcare market, creates a significant competitive advantage by embedding iCAD's technology into radiologists' existing workflows. This frictionless implementation approach should accelerate adoption across Microsoft's network of 17,000+ healthcare facilities nationwide.

The cloud-hosted delivery model supports iCAD's transition toward more predictable SaaS revenue streams versus traditional one-time licensing. While specific financial terms weren't disclosed, the substantial distribution footprint represents a meaningful opportunity to scale solutions across the healthcare ecosystem.

The timing aligns perfectly with their FDA clearance of ProFound Detection Version 4.0, allowing iCAD to launch their most advanced technology (with 22% better detection of complex cancers) through this expanded distribution channel. For investors, this partnership demonstrates iCAD's ability to secure high-value collaborations while continuing to advance their core technology platform.

iCAD collaborates with Microsoft to offer radiology providers the option for automated patient reporting on mammography results through PowerScribe integration

NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD’s ProFound Breast Health Suite on Microsoft’s Precision Imaging Network. The iCAD and Microsoft collaboration provides access to automated radiology mammography reporting for patients through Microsoft’s advanced radiology reporting platform, PowerScribe. iCAD’s ProFound AI^® Breast Health Suite will be fully cloud-hosted across Microsoft’s extensive network, providing radiologists and healthcare providers with streamlined, AI-driven insights that help to elevate breast health detection, enhance clinical workflows, and ultimately aim to improve patient outcomes.

A majority of radiologists across the U.S. rely on PowerScribe, for its AI-based radiology reporting and workflow capabilities. As a mammography solution offered through Precision Imaging Network, iCAD will be uniquely optimized for integration within PowerScribe to enable radiologists to efficiently create, review, and share diagnostic reports, leveraging features that standardize language and automate routine tasks. Precision Imaging Network securely hosts third-party AI models with standardized integrations into radiology workflows.

“We are excited to partner with Microsoft to expand access to our AI solutions for breast cancer detection across a broader network of healthcare providers,” said Dana Brown, CEO and President of iCAD. “This collaboration supports our growth strategy by expanding the reach of our industry-leading technology, driving deeper market penetration, and advancing our transition to a SaaS model. Integrating ProFound AI results in the PowerScribe report aligns with our shared mission to improve cancer detection and care while empowering radiologists to deliver earlier, more accurate interpretations with greater confidence and efficiency.”

“With the integration of iCAD’s ProFound suite of breast health offerings with our Precision Imaging Network and PowerScribe solutions, we will help provide radiologists and patients with more accurate, actionable breast health insights, while streamlining mammography screening workflow, driving clinical and operational value at scale.” said Vikram Chhabra, General Manager, Diagnostic Solutions at Microsoft.

Precision Imaging Network provides streamlined access to a curated collection of third-party AI models through a single point of integration, empowering radiologists and healthcare systems to leverage AI insights directly within existing clinical workflows. Connecting over 17,000 healthcare facilities nationwide, Precision Imaging Network seamlessly integrates iCAD’s ProFound AI® technology, making it readily available to radiologists and specialty physicians across diverse healthcare environments. By embedding iCAD’s capabilities in cancer detection and density assessment, Precision Imaging Network delivers targeted, patient-specific insights with unprecedented efficiency.

This collaboration follows recent FDA clearance of iCAD’s ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT), marking a new era in AI-powered breast cancer detection. This fourth-generation AI solution utilizes advanced deep learning convolutional neural networks, achieving a 22% improvement in detecting complex and aggressive cancer subtypes over previous versions, with significant enhancements for dense breast tissue. ProFound Detection Version 4.0 is specifically designed to navigate the intricacies of DBT exams, achieving an 18% reduction in lesion markings to minimize potential false positives and streamline radiologists’ workflows. The solution also incorporates priors into the AI analysis, allowing radiologists to better assess changes over time, further supporting more accurate, personalized patient screening assessments.

iCAD will showcase this next-generation AI collaboration, along with its end-to-end breast health AI suite and the recently cleared ProFound Detection Version 4.0, at the upcoming 2025 SIIM25 Annual Meeting + InformaticsTECH Expo in Portland, OR from May 21st to May 23rd. Visit iCAD’s event page to learn more and book a live demonstration: https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/siim-2025/.

About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis.  For more information, including the latest in regulatory clearances, please visit www.icadmed.com.

Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

CONTACTS

Media Inquiries:
pr@icadmed.com

Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com

FAQ

What benefits does iCAD's (ICAD) collaboration with Microsoft's Precision Imaging Network offer radiologists?

The collaboration provides radiologists with cloud-hosted AI mammography solutions, automated reporting through PowerScribe integration, and streamlined workflows. It enables efficient creation and sharing of diagnostic reports while standardizing language and automating routine tasks across 17,000 healthcare facilities.

How much does iCAD's ProFound Detection 4.0 improve cancer detection compared to previous versions?

ProFound Detection Version 4.0 achieves a 22% improvement in detecting complex and aggressive cancer subtypes compared to previous versions, with particular enhancements for dense breast tissue. It also reduces lesion markings by 18% to minimize false positives.

When will iCAD showcase its Microsoft collaboration and ProFound Detection 4.0 at SIIM25?

iCAD will showcase its Microsoft collaboration and ProFound Detection 4.0 at the SIIM25 Annual Meeting + InformaticsTECH Expo in Portland, OR from May 21st to May 23rd, 2025.

What are the key features of iCAD's ProFound AI integration with Microsoft PowerScribe?

The integration offers automated radiology mammography reporting, AI-driven insights for breast health detection, standardized language features, and automated routine tasks. It's optimized specifically for PowerScribe to enhance clinical workflows and improve patient outcomes.

How does iCAD's ProFound Detection 4.0 handle prior mammogram comparisons?

ProFound Detection 4.0 incorporates prior mammograms into its AI analysis, allowing radiologists to better assess changes over time and support more accurate, personalized patient screening assessments.